We have used homozygous albumin enhancer/promoter-driven urokinase-type
plasminogen activator/severe combined immunodeficient (uPA/SCID) mice as hosts for …

Background & Aims Antiviral agents including entecavir (ETV) suppress the replication of the
hepatitis B virus (HBV) genome in human hepatocytes, but they do not reduce the …

We previously produced mice with human hepatocyte (h-hep) chimeric livers by
transplanting h-heps into albumin enhancer/promoter-driven urokinase-type plasminogen …

Cryopreserved human (h-) hepatocytes are currently regarded as the best in vitro model for
predicting human intrinsic clearance of xenobiotics. Although fresh h-hepatocytes have …

Background & Aims While certain nucleos (t) ide reverse transcriptase inhibitors (NRTIs) are
efficacious in treating HBV infection, their effects are yet to be optimized and the emergence …

We performed in vivo and in vitro studies to determine the induction of human cytochrome
P450 (CYP) using chimeric mice with humanized liver (PXB-mice®) and human hepatocytes …

Troglitazone (Tro) is a thiazolidinedione antidiabetic drug that was withdrawn from the
market due to its association with idiosyncratic severe liver injury. Tro has never induced …

The induction of cytochrome P450 (P450) enzymes is one of the risk factors for drug-drug
interactions (DDIs). To date, the human pregnane X receptor (PXR)-mediated CYP3A4 …

Human-specific or disproportionately abundant human metabolites of drug candidates that
are not adequately formed and qualified in preclinical safety assessment species pose an …

The influence of transporters on the pharmacokinetics of drugs is being increasingly
recognized, and DDIs via transporters may be a risk factor for adverse events. Cyclosporine …